|
EP1668143B1
(en)
*
|
2003-09-30 |
2013-03-20 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
DK2561073T3
(en)
|
2010-04-23 |
2016-12-12 |
Univ Massachusetts |
Aav vectors targeted to central nervous system and methods of use thereof
|
|
CA2826273C
(en)
|
2011-02-10 |
2021-11-02 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
|
CN103502458B
(zh)
|
2011-02-17 |
2016-11-16 |
宾夕法尼亚大学托管会 |
用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
|
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
EP3470523A1
(en)
*
|
2012-05-09 |
2019-04-17 |
Oregon Health & Science University |
Adeno associated virus plasmids and vectors
|
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
|
US20140219964A1
(en)
|
2013-02-07 |
2014-08-07 |
Children's Medical Center Corporation |
Methods for inducing cardiomyocyte proliferation
|
|
EP2970946A4
(en)
*
|
2013-03-13 |
2016-09-07 |
Philadelphia Children Hospital |
ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
|
|
ES2926774T3
(es)
*
|
2013-03-15 |
2022-10-28 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para vectores AAV de doble unión de glicano
|
|
BR112015021036A2
(pt)
|
2013-03-15 |
2017-10-10 |
Univ Pennsylvania |
composições e métodos para tratar mps1
|
|
PT3628334T
(pt)
|
2014-03-21 |
2023-09-26 |
Genzyme Corp |
Terapia genética para retinopatia pigmentar
|
|
US10746742B2
(en)
|
2014-04-25 |
2020-08-18 |
Oregon Health & Science University |
Methods of viral neutralizing antibody epitope mapping
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
PT4012035T
(pt)
|
2014-09-16 |
2025-02-11 |
Genzyme Corp |
Vetores virais adenoassociados para tratar o glaucoma de miocilina (mioc)
|
|
EP4012035B1
(en)
|
2014-09-16 |
2024-11-06 |
Genzyme Corporation |
Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
|
|
WO2016054557A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Novel high efficiency library-identified aav vectors
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
WO2016065001A1
(en)
|
2014-10-21 |
2016-04-28 |
University Of Massachusetts |
Recombinant aav variants and uses thereof
|
|
EP3215191B1
(en)
|
2014-11-05 |
2024-08-14 |
Voyager Therapeutics, Inc. |
Aadc polynucleotides for the treatment of parkinson's disease
|
|
CN114717264A
(zh)
|
2014-11-14 |
2022-07-08 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
|
KR20230145206A
(ko)
|
2014-11-14 |
2023-10-17 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
IL310375B2
(en)
|
2015-01-20 |
2025-05-01 |
Genzyme Corp |
Analytical ultracentrifugation for characterization of recombinant viral particles
|
|
CA3255657A1
(en)
|
2015-02-10 |
2025-12-01 |
Genzyme Corporation |
VARIANT RNAi
|
|
EA201791803A1
(ru)
|
2015-02-10 |
2017-11-30 |
Джензим Корпорейшн |
Улучшенная доставка вирусных частиц в полосатое тело и кору больших полушарий
|
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
PL3298134T3
(pl)
|
2015-05-16 |
2023-09-18 |
Genzyme Corporation |
Edycja genów mutacji głęboko intronowych
|
|
CA2988471A1
(en)
*
|
2015-07-28 |
2017-02-02 |
University Of Massachusetts |
Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
|
|
WO2017070516A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
|
AU2016362477A1
(en)
|
2015-12-02 |
2018-06-14 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
|
EP3387138B2
(en)
|
2015-12-11 |
2026-05-27 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
|
US11015174B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV8
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
EP3992283A1
(en)
|
2015-12-11 |
2022-05-04 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
|
SG10201912935WA
(en)
|
2015-12-15 |
2020-02-27 |
Genzyme Corp |
Adeno-associated viral vectors for treating mucolipidosis type ii
|
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
MA43968A
(fr)
|
2016-02-03 |
2018-12-12 |
Univ Pennsylvania |
Thérapie génique pour traiter la mucopolysaccharidose de type i
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
EP3440210A4
(en)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
COMPOSITIONS AND METHOD FOR SELECTIVELY INHIBITING THE EXPRESSION OF GRAINYHEAD LIKE PROTEIN
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
US11253612B2
(en)
|
2016-04-15 |
2022-02-22 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type II
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
WO2017197355A2
(en)
|
2016-05-13 |
2017-11-16 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
|
US10584337B2
(en)
|
2016-05-18 |
2020-03-10 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
IL297576B2
(en)
|
2016-05-18 |
2024-02-01 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
CN106093369B
(zh)
*
|
2016-06-29 |
2017-10-20 |
福建农林大学 |
Bt水稻对非靶标害虫褐飞虱的安全性评价方法
|
|
HUE053747T2
(hu)
|
2016-08-15 |
2021-07-28 |
Genzyme Corp |
Eljárások AAV kimutatására
|
|
EP3831281B1
(en)
|
2016-08-30 |
2026-02-25 |
The Regents of The University of California |
Devices and systems for biomedical targeting and delivery
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
KR20190075964A
(ko)
|
2016-10-13 |
2019-07-01 |
유니버시티 오브 매사추세츠 |
Aav 캡시드 설계
|
|
US20230048025A1
(en)
*
|
2016-12-22 |
2023-02-16 |
Oregon Health & Science University |
Adeno associated viral vectors
|
|
MX2019013172A
(es)
|
2017-05-05 |
2020-09-07 |
Voyager Therapeutics Inc |
Composiciones y metodos para tratar la enfermedad de huntington.
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
CA3068328A1
(en)
|
2017-07-06 |
2019-01-10 |
The Trustees Of The University Of Pennsylvania |
Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
|
|
CA3070087A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
DK3684423T5
(da)
|
2017-09-20 |
2024-08-26 |
4D Molecular Therapeutics Inc |
Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
|
|
MX2020003095A
(es)
|
2017-09-22 |
2020-10-15 |
Genzyme Corp |
Arni variante.
|
|
EP3684938A1
(en)
|
2017-09-22 |
2020-07-29 |
The Trustees of the University of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
MX2020003042A
(es)
|
2017-09-29 |
2020-11-18 |
Voyager Therapeutics Inc |
Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
US11766489B2
(en)
|
2017-11-27 |
2023-09-26 |
4D Molecular Therapeutics, Inc. |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
|
AU2019215152A1
(en)
|
2018-02-01 |
2020-08-20 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
|
|
WO2019152841A1
(en)
*
|
2018-02-01 |
2019-08-08 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for pah gene transfer and methods of use thereof
|
|
US11306329B2
(en)
|
2018-02-19 |
2022-04-19 |
City Of Hope |
Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
|
|
JP7374119B2
(ja)
|
2018-04-05 |
2023-11-06 |
ジェネトン |
減少した肝臓向性を有するＡＡＶ９とＡＡＶｒｈ７４とのハイブリッド組換えアデノ随伴ウイルス血清型
|
|
CA3099958A1
(en)
|
2018-04-16 |
2019-10-24 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating duchenne muscular dystrophy
|
|
WO2019213668A1
(en)
*
|
2018-05-04 |
2019-11-07 |
Oregon Health & Science University |
Human anti-aav2 capsid polyclonal antibody epitopes
|
|
CN112424359A
(zh)
|
2018-05-15 |
2021-02-26 |
沃雅戈治疗公司 |
用于治疗帕金森氏病的组合物和方法
|
|
WO2019236995A1
(en)
|
2018-06-08 |
2019-12-12 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
WO2020023612A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
TW202509215A
(zh)
|
2018-08-03 |
2025-03-01 |
美商健臻公司 |
針對α-突觸核蛋白的變體RNAi
|
|
US12281321B2
(en)
|
2018-09-28 |
2025-04-22 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
WO2020072849A1
(en)
|
2018-10-04 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
AU2019354793A1
(en)
|
2018-10-05 |
2021-05-13 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding AAV production proteins
|
|
CN120349985A
(zh)
|
2018-10-12 |
2025-07-22 |
建新公司 |
通过肝导向基因替代疗法治疗严重pku的改良的人pah的产生
|
|
WO2020081490A1
(en)
|
2018-10-15 |
2020-04-23 |
Voyager Therapeutics, Inc. |
EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
CN119390787A
(zh)
*
|
2019-01-31 |
2025-02-07 |
俄勒冈健康与科学大学 |
用于aav衣壳的使用转录依赖性定向进化的方法
|
|
US20220154210A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
EP3931335A2
(en)
|
2019-02-25 |
2022-01-05 |
Novartis AG |
Compositions and methods to treat bietti crystalline dystrophy
|
|
EP3930694A1
(en)
|
2019-02-28 |
2022-01-05 |
Regeneron Pharmaceuticals, Inc. |
Adeno-associated virus vectors for the delivery of therapeutics
|
|
EP3953484A4
(en)
|
2019-04-12 |
2023-04-12 |
University of Massachusetts |
Aav-mediated gene therapy for maple syrup urine disease (msud)
|
|
JP7707081B2
(ja)
*
|
2019-05-17 |
2025-07-14 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
網膜細胞を標的とした最適化された遺伝子治療
|
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
|
CN114787180A
(zh)
*
|
2019-10-17 |
2022-07-22 |
斯特里迪比奥公司 |
用于治疗c型尼曼-匹克病的腺相关病毒载体
|
|
WO2021087366A1
(en)
*
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Compositions and methods for genome engineering
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
EP4208322A4
(en)
|
2020-09-04 |
2024-09-11 |
Milwaukee Electric Tool Corporation |
Chainsaw
|
|
KR20230079172A
(ko)
|
2020-10-01 |
2023-06-05 |
젠자임 코포레이션 |
간-유도 유전자 대체 요법에 의한 pku의 치료를 위한 인간 pah 발현 카세트
|
|
MX2023008826A
(es)
|
2021-02-01 |
2023-09-15 |
Regenxbio Inc |
Terapia génica para lipofuscinosis neuronal ceroidea.
|
|
AU2022318664A1
(en)
|
2021-07-30 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
US20240254483A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
CN119317718A
(zh)
*
|
2022-01-25 |
2025-01-14 |
宾夕法尼亚州大学信托人 |
用于改善心脏转导和肝脏去靶向的aav衣壳
|
|
CA3255627A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
|
|
EP4554967A2
(en)
|
2022-07-12 |
2025-05-21 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
CN121586778A
(zh)
|
2023-04-26 |
2026-02-27 |
赛诺菲 |
宿主细胞系以及用于鉴定和使用此类宿主细胞系的方法
|
|
KR20260082361A
(ko)
*
|
2023-08-31 |
2026-06-04 |
디노 테라퓨틱스, 인코포레이티드 |
캡시드 폴리펩타이드 및 이의 사용 방법
|
|
WO2025128817A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
Artificial micrornas targeting tau
|
|
WO2025160434A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting huntington's disease
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|
|
WO2025188755A1
(en)
|
2024-03-04 |
2025-09-12 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
|
|
WO2025226841A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Gene therapy approach for treating disorders associated with tnnt2
|
|
WO2025226842A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Expression control by drg-expressed mirnas
|
|
WO2026011009A1
(en)
|
2024-07-02 |
2026-01-08 |
Kate Therapeutics, Inc. |
Compositions and methods for muscle disorders
|
|
WO2026011008A1
(en)
|
2024-07-02 |
2026-01-08 |
Kate Therapeutics, Inc. |
Expression control by skeletal muscle-expressed mirnas
|
|
WO2026030242A1
(en)
|
2024-07-29 |
2026-02-05 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy
|
|
WO2026030244A1
(en)
|
2024-07-30 |
2026-02-05 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a
|
|
WO2026050402A1
(en)
|
2024-08-29 |
2026-03-05 |
Kate Therapeutics, Inc. |
Liver de-targeted muscle tropic capsids
|
|
WO2026150302A1
(en)
|
2025-01-09 |
2026-07-16 |
Novartis Ag |
Novel aav rep/cap encoding constructs
|